Pharmaceutical Companies Compete to Secure Long-Term Cooperation with China Health Resource Inc.

Share Article

GAP certification in Angelica production and authorization to use the “Sichuan Angelica” geographical logo make China Health Resource Inc. a desirable enterprise to partner with

“Entering the international Chinese herbal medicine market is a great opportunity for us, and selecting a respectable enterprise to join forces with will ensure our company continues to provide a variety of products of the utmost quality.”

China Health Resource Inc. (OTCBB: CHRI), a leading Chinese pharmaceutical company specializing in producing, processing and commercializing Dahurian Angelica Root (DAR), today announced the company is entering the international Chinese herbal medicine market and is seeking cooperation amongst a number of foreign enterprises.

China Health Resource Inc. is well known for its high-quality Angelica in the native market of Sichuan, enticing many pharmaceutical enterprises to work closely with the company. At present, various well-known domestic Chinese pharmaceutical companies are competing to negotiate long-term cooperation with China Health Resource Inc., including foreign enterprises from the United States and Japan.

“There is great demand for high-quality Angelica as raw materials in the pharmaceutical market, primarily in pharmaceutical export markets,” stated Jiayin Wang, CEO, China Health Resource Inc. “Entering the international Chinese herbal medicine market is a great opportunity for us, and selecting a respectable enterprise to join forces with will ensure our company continues to provide a variety of products of the utmost quality.”

Two enterprises currently discussing long-term cooperation with China Health Resource Inc. are Sichuan Zhiyuan Aquarious Pharmacy co.ltd and Chengdou Zhonghui Pharmacy co.ltd. Sichuan Zhiyuan Aquarious Pharmacy co.ltd has produced more than 50 branches in China, and has established a solid relationship with dealers in the United States, Australia and several others. Chengdou Zhonghui Pharmacy co.ltd is a subsidiary of Sichuan Zhonghui (Group) Pharmacy co.ltd, and is primarily engaged in researching the production and sales of Chinese medicine, Western medicine, health products and herbal extracts.

Additional information about China Health Resource Inc., Sichuan Zhiyuan Aquarious Pharmacy co.ltd and Chengdou Zhonghui Pharmacy co.ltd can be found by visiting http://ChinaHealthResource.com.

About CHRI
China Health Resource Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People's Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Press Contact:
Rebecca Binny-Hallmark
China Health Resource Inc.
(323) 403-3829
Rebecca(dot)hallmark(at)evotech(dot)com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rebecca Hallmark
Visit website

Media